XNK Therapeutics

XNK Therapeutics AB is an immunotherapy company focusing its efforts on preventing and treating cancer by developing novel NK cell-based therapies.

The company’s platform-technology and leading investigational autologous drug candidate, CellProtect, has ideal properties for targeting cancers, including settings where allogeneic cell products are not readily applicable. It is foreseen that the product will bring a critical component to tomorrow’s cancer treatment strategies.